Subject of the day
XVIVO.ST
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.
| Line | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | $218.59M | $178.29M | $226.14M | $240.96M |
| Gross profit | $160.37M | $132.66M | $164.08M | $171.04M |
| Operating income | $26.57M | $7.08M | $36.82M | $31.94M |
| Net income | -$12.40M | $1.57M | $31.65M | $36.30M |
| Diluted EPS | -0.39 | 0.05 | 1.01 | 1.15 |
| Free cash flow | -$15.25M | $8.80M | $86.93M | $65.34M |
$307.20
▲ +2.20 (+0.7%)
| 52w hi | $307.20 |
|---|---|
| 52w lo | $160.80 |
| Vol | 58.78K |
| As of | Aug 13 |
Our score +0.23
| Short | -0.15 |
|---|---|
| Medium | +0.35 |
| Long | +0.76 |
computed 2026-08-13
Xvivo Perfusion AB (publ)
Healthcare · Medical Devices
| Market cap | $9.73B |
|---|---|
| Enterprise value | $9.55B |
| Trailing P/E | 110.36x |
| Forward P/E | 52.28x |
| EV / EBITDA | 60.34x |
| P / S (ttm) | 10.87x |
| Profit margin | 9.9% |
| Return on equity | 4.1% |
| Revenue growth | +34.0% |
| Earnings growth | +935.1% |
| Debt / equity | 5.53 |
| Beta vs SPX | 0.42 |
|---|---|
| Corr SPX | 0.13 |
| Annual vol | 52.0% |
| Annual ret | -19.7% |
| Sharpe | -0.38 |
| Max DD | -72.0% |
Window: 504 trading days (490 obs)
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.44 | |
| Sector | +0.12 | |
| Technical | +0.00 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-08-13
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Aug 13 | $308.80 | $312.60 | $303.80 | — | 58.78K |
| Aug 12 | $308.40 | $310.40 | $304.20 | $307.20 | 129.78K |
| Aug 11 | $279.20 | $314.80 | $279.00 | $305.00 | 295.81K |
| Aug 10 | $279.00 | $283.00 | $278.00 | $281.00 | 52.61K |
| Aug 7 | $271.60 | $283.40 | $271.40 | $278.60 | 62.51K |